Vafidemstat - Revision history

Prab: CSV import

2025-02-20T01:28:07Z

CSV import

← Older revision		Revision as of 01:28, 20 February 2025
Line 47:		Line 47:
	[[Category:Histone deacetylase inhibitors]]		[[Category:Histone deacetylase inhibitors]]
	[[Category:Experimental drugs]]		[[Category:Experimental drugs]]
			<gallery>
			File:Vafidemstat.svg\|Vafidemstat
			</gallery>

Prab: CSV import

2025-02-13T03:38:16Z

CSV import

← Older revision		Revision as of 03:38, 13 February 2025
Line 1:		Line 1:
	== Vafidemstat ==		{{Short description\|An overview of the drug Vafidemstat}}
			{{Drugbox
			\| verifiedfields = changed
			\| verifiedrevid = 123456789
			\| image = Vafidemstat.svg
			\| image_size = 250px
			\| image_alt = Chemical structure of Vafidemstat
			}}

	[[~~File:Vafidemstat~~.~~svg\|thumb\|Chemical structure of Vafidemstat~~]]		'''Vafidemstat''' is a novel [[pharmaceutical drug]] under investigation for its potential therapeutic effects in various [[neuropsychiatric disorders]]. It is classified as a [[histone deacetylase inhibitor]] (HDAC inhibitor), which modulates the expression of genes by altering the acetylation status of histones.

	~~'''~~Vafidemstat~~''' is a pharmaceutical compound that~~ functions as a [[~~histone deacetylase~~]] ~~(HDAC) inhibitor~~. It is ~~primarily being investigated for~~ its potential therapeutic effects in ~~treating various~~ [[~~neurodegenerative~~ disorders]] and [[~~psychiatric conditions~~]].		==Mechanism of Action==
			Vafidemstat functions primarily as an HDAC inhibitor. By inhibiting histone deacetylases, it increases the acetylation of histone proteins, leading to a more relaxed chromatin structure and increased [[gene expression]]. This mechanism is thought to underlie its potential therapeutic effects in [[neuropsychiatric disorders]] by modulating the expression of genes involved in [[neurotransmission]], [[neuroplasticity]], and [[inflammation]].

	== ~~Mechanism of Action~~ ==		==Therapeutic Applications==
	Vafidemstat ~~works by inhibiting the activity of histone deacetylases, which are enzymes involved~~ in ~~the removal~~ of acetyl groups from histone proteins. This inhibition leads to an increase in histone acetylation, resulting in a more open chromatin structure and enhanced [[gene expression]]. By modulating gene expression, Vafidemstat may influence pathways involved in [[neuroinflammation]], [[synaptic plasticity]], ~~and [[neuroprotection]].~~		Vafidemstat is being investigated for its use in treating a variety of neuropsychiatric conditions, including:

	~~== Clinical Development ==~~		* [[Schizophrenia]]
	~~Vafidemstat is currently undergoing clinical trials to evaluate its efficacy and safety in treating conditions such as~~ [[~~Alzheimer's disease~~]], [[~~schizophrenia~~]]~~, and~~ [[~~borderline personality~~ disorder]]~~. Early studies have shown promise in improving cognitive function and reducing symptoms associated with these disorders.~~		* [[Bipolar disorder]]
			* [[Major depressive disorder]]
			* [[Autism spectrum disorder]]

	~~== Potential Applications ==~~		The drug's ability to modulate gene expression may help alleviate symptoms associated with these disorders by restoring normal patterns of neuronal activity and connectivity.
	The ~~potential applications~~ of ~~Vafidemstat extend beyond neurodegenerative and psychiatric disorders. Research is ongoing to explore its effects in other areas such as [[cancer]]~~ and ~~[[autoimmune diseases]], where HDAC inhibitors have shown therapeutic potential~~.

	== ~~Side Effects~~ ==		==Clinical Trials==
	~~As with other HDAC inhibitors,~~ Vafidemstat ~~may cause side effects~~, ~~including fatigue, gastrointestinal disturbances~~, and ~~hematological changes. The safety profile~~ of ~~Vafidemstat is still being established through clinical trials~~.		Vafidemstat is currently undergoing clinical trials to evaluate its safety and efficacy. These trials are designed to assess its impact on symptom severity, cognitive function, and overall quality of life in patients with neuropsychiatric disorders.

	== Related Pages ==		==Side Effects==
			As with many HDAC inhibitors, potential side effects of Vafidemstat may include:

			* [[Gastrointestinal disturbances]]
			* [[Fatigue]]
			* [[Headache]]
			* [[Dizziness]]

			Ongoing clinical trials aim to further elucidate the safety profile of Vafidemstat.

			==Research and Development==
			The development of Vafidemstat is part of a broader effort to create targeted therapies for complex neuropsychiatric conditions. By focusing on epigenetic modulation, researchers hope to provide more effective treatments with fewer side effects compared to traditional [[psychotropic medications]].

			==Related Pages==
	* [[Histone deacetylase inhibitor]]		* [[Histone deacetylase inhibitor]]
	* [[~~Neurodegenerative disease~~]]		* [[Neuropsychiatric disorder]]
	* [[~~Psychiatric disorder~~]]		* [[Epigenetics]]

	~~== References ==~~
	~~{{Reflist}}~~

	[[Category:Pharmaceutical drugs]]		[[Category:Pharmaceutical drugs]]
	[[Category:Histone deacetylase inhibitors]]		[[Category:Histone deacetylase inhibitors]]
			[[Category:Experimental drugs]]

Prab: CSV import

2025-02-09T11:54:32Z

CSV import

← Older revision		Revision as of 11:54, 9 February 2025
Line 1:		Line 1:
	Vafidemstat		== Vafidemstat ==

	Vafidemstat is a novel pharmacological compound currently under investigation for its potential therapeutic effects in various neuropsychiatric and neurodegenerative disorders. It is classified as an epigenetic modulator, specifically targeting the enzyme lysine-specific demethylase 1 (LSD1). By inhibiting LSD1, vafidemstat is believed to influence gene expression patterns that are dysregulated in certain diseases.		[[File:Vafidemstat.svg\|thumb\|Chemical structure of Vafidemstat]]

	~~==Mechanism of Action==~~		'''Vafidemstat''' is a pharmaceutical compound that functions as a [[histone deacetylase]] (HDAC) inhibitor. It is primarily being investigated for its potential therapeutic effects in treating various [[neurodegenerative disorders]] and [[psychiatric conditions]].
	Vafidemstat functions as ~~an inhibitor of LSD1, an enzyme that plays~~ a ~~critical role in the demethylation of~~ histone ~~proteins~~. ~~Histones are proteins around which DNA~~ is wound, and their modification can significantly impact gene expression. LSD1 removes methyl groups from specific lysine residues on histones, thereby influencing chromatin structure and gene transcription. By inhibiting LSD1, vafidemstat may alter the expression of genes involved in ~~neuroinflammation, synaptic plasticity,~~ and ~~neuronal survival~~.

	==~~Therapeutic Applications~~==		== Mechanism of Action ==
	Vafidemstat ~~is being explored for its potential use~~ in ~~treating~~ a ~~variety of conditions~~, ~~including:~~		Vafidemstat works by inhibiting the activity of histone deacetylases, which are enzymes involved in the removal of acetyl groups from histone proteins. This inhibition leads to an increase in histone acetylation, resulting in a more open chromatin structure and enhanced [[gene expression]]. By modulating gene expression, Vafidemstat may influence pathways involved in [[neuroinflammation]], [[synaptic plasticity]], and [[neuroprotection]].

	* '''Alzheimer's Disease''': By modulating gene expression, vafidemstat may help reduce neuroinflammation and ~~improve cognitive function~~ in ~~patients with~~ Alzheimer's disease.		== Clinical Development ==
	* '''Schizophrenia''': The drug's ability to influence synaptic plasticity and neurotransmitter systems may offer benefits in managing symptoms of schizophrenia.		Vafidemstat is currently undergoing clinical trials to evaluate its efficacy and safety in treating conditions such as [[Alzheimer's disease]], [[schizophrenia]], and [[borderline personality disorder]]. Early studies have shown promise in improving cognitive function and reducing symptoms associated with these disorders.
	* '''Borderline Personality Disorder''': Vafidemstat is being studied for its potential to stabilize mood and ~~reduce impulsivity in individuals with~~ borderline personality disorder.

	==~~Clinical Trials~~==		== Potential Applications ==
	~~Several clinical trials are underway to evaluate the safety~~ and ~~efficacy of vafidemstat in different patient populations~~. ~~These trials aim~~ to ~~assess the drug's impact on cognitive function, behavioral symptoms~~, ~~and overall quality of life~~.		The potential applications of Vafidemstat extend beyond neurodegenerative and psychiatric disorders. Research is ongoing to explore its effects in other areas such as [[cancer]] and [[autoimmune diseases]], where HDAC inhibitors have shown therapeutic potential.

	==Side Effects ~~and Safety~~==		== Side Effects ==
	As with ~~any investigational drug~~, ~~the safety profile of vafidemstat is being closely monitored. Common~~ side effects ~~observed in clinical trials include mild~~ gastrointestinal disturbances~~, headache~~, and ~~fatigue~~. ~~Long-term~~ safety ~~data are~~ still being ~~collected~~.		As with other HDAC inhibitors, Vafidemstat may cause side effects, including fatigue, gastrointestinal disturbances, and hematological changes. The safety profile of Vafidemstat is still being established through clinical trials.

	==~~Research and Development~~==		== Related Pages ==
	Vafidemstat is being developed by Oryzon Genomics, a biopharmaceutical company specializing in epigenetic therapies. The drug is part of a broader effort to develop targeted treatments that address the underlying molecular mechanisms of complex diseases.		* [[Histone deacetylase inhibitor]]
			* [[Neurodegenerative disease]]
			* [[Psychiatric disorder]]

	==~~Also see~~==		== References ==
	* [[Lysine-specific demethylase 1]]		{{Reflist}}
	* [[Epigenetic therapy]]
	* [[Neuroinflammation]]
	* [[Histone modification]]
	* [[Alzheimer's disease]]
	* [[Schizophrenia]]

	~~{{Drug-stub}}~~		[[Category:Pharmaceutical drugs]]
	~~{{Neuroscience-stub}}~~		[[Category:Histone deacetylase inhibitors]]

	~~[[Category:Epigenetic drugs]]~~
	[[Category:~~Investigational~~ drugs]]
	[[Category:~~Neuropsychiatric treatments~~]]

Prab: CSV import

2024-12-07T15:38:13Z

CSV import

New page

Vafidemstat

Vafidemstat is a novel pharmacological compound currently under investigation for its potential therapeutic effects in various neuropsychiatric and neurodegenerative disorders. It is classified as an epigenetic modulator, specifically targeting the enzyme lysine-specific demethylase 1 (LSD1). By inhibiting LSD1, vafidemstat is believed to influence gene expression patterns that are dysregulated in certain diseases.

==Mechanism of Action==
Vafidemstat functions as an inhibitor of LSD1, an enzyme that plays a critical role in the demethylation of histone proteins. Histones are proteins around which DNA is wound, and their modification can significantly impact gene expression. LSD1 removes methyl groups from specific lysine residues on histones, thereby influencing chromatin structure and gene transcription. By inhibiting LSD1, vafidemstat may alter the expression of genes involved in neuroinflammation, synaptic plasticity, and neuronal survival.

==Therapeutic Applications==
Vafidemstat is being explored for its potential use in treating a variety of conditions, including:

* '''Alzheimer's Disease''': By modulating gene expression, vafidemstat may help reduce neuroinflammation and improve cognitive function in patients with Alzheimer's disease.
* '''Schizophrenia''': The drug's ability to influence synaptic plasticity and neurotransmitter systems may offer benefits in managing symptoms of schizophrenia.
* '''Borderline Personality Disorder''': Vafidemstat is being studied for its potential to stabilize mood and reduce impulsivity in individuals with borderline personality disorder.

==Clinical Trials==
Several clinical trials are underway to evaluate the safety and efficacy of vafidemstat in different patient populations. These trials aim to assess the drug's impact on cognitive function, behavioral symptoms, and overall quality of life.

==Side Effects and Safety==
As with any investigational drug, the safety profile of vafidemstat is being closely monitored. Common side effects observed in clinical trials include mild gastrointestinal disturbances, headache, and fatigue. Long-term safety data are still being collected.

==Research and Development==
Vafidemstat is being developed by Oryzon Genomics, a biopharmaceutical company specializing in epigenetic therapies. The drug is part of a broader effort to develop targeted treatments that address the underlying molecular mechanisms of complex diseases.

==Also see==
* [[Lysine-specific demethylase 1]]
* [[Epigenetic therapy]]
* [[Neuroinflammation]]
* [[Histone modification]]
* [[Alzheimer's disease]]
* [[Schizophrenia]]

{{Drug-stub}}
{{Neuroscience-stub}}

[[Category:Epigenetic drugs]]
[[Category:Investigational drugs]]
[[Category:Neuropsychiatric treatments]]